|Bid||1.65 x 1000|
|Ask||1.95 x 500|
|Day's range||1.70 - 1.75|
|52-week range||1.35 - 8.00|
|PE ratio (TTM)||N/A|
|Earnings date||6 Mar 2018 - 12 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||7.79|
Trevena Inc. shares jumped in the extended session Tuesday after the biotech company said the Food and Drug Administration accepted for review a marketing application for its opioid-replacement painkiller. ...
Trevena, Inc. (NASDAQ:TRVN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for OLINVO™ (oliceridine) Injection. The Company expects that the PDUFA date for the NDA will be in the fourth quarter of 2018. OLINVO is an investigational product for the management of moderate to severe acute pain. It is the first G protein biased ligand of the mu receptor designed to provide IV opioid pain relief with fewer associated adverse effects.